Advertisement

Topics

Latest "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" News Stories - Page: 2

07:05 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" found in our extensive news archives from over 250 global news sources.

More Information about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal for you to read. Along with our medical data and news we also list Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Companies for you to search.

Showing "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" News Articles 26–50 of 2,400+

Tuesday 19th February 2019

Sage Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

Planned U.S. commercial launch of ZULRESSO™ (brexanolone) injection, if approved, on track for June 2019, based on PDUFA target date of March 19, 2019 and anticipated DEA scheduling Topline data from Phase 3 trial of SAGE-217 in MDD expected in Q4 2019 or 1Q 2020 Neurology and neuropsychiatry franchises continue to progress with ...


Enzymatica AB: Strong sales in the fourth quarter, but lower sales for full-year 2018 driven by restrictions in Germany

                                                                                       Interim report for Enzymatica AB (publ)                                                                                   ...

The Magic Feather Effect: Placebos and the Power of Belief in Alternative Medicine

In her book The Magic Feather Effect, journalist Melanie Warner covers placebo research, shows that alternative medicine is placebo medicine, takes a "try it yourself" approach, and gives belief and anecdotes more credit than they deserve.


Monday 18th February 2019

[Articles] Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Participants' percentage abstinence was significantly higher in both BUP-XR groups than in the placebo group. Treatment with BUP-XR was also well tolerated. The availability of this monthly formulation, delivered by health-care providers, represents an advance in treatment for opioid use disorder that enhances the benefits of buprenorphine by delivering sustained, optimal exposure, while reducing ...

[Comment] Opioid addiction: long-acting formulations for a long-term disorder

Barbara Haight and colleagues1 report findings from their phase 3 trial, providing evidence that a novel, monthly, long-acting buprenorphine formulation (BUP-XR) is both safe and efficacious in reducing illicit opioid use, compared with placebo. Extended-release buprenorphine (Sublocade; Indivior, Richmond, VA, USA), given as monthly injections, is the latest drug approved for opioid use disorders...

Birch pollen allergen immunotherapy normalizes nasal gene-expression and microbial community

(University of Helsinki) According to a new study, birch pollen allergen immunotherapy modifies the gene expression and microbiome profile of the nasal epithelium to correspond to those of healthy controls.

Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis

Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis Primary endpoint of the trial was not met, no statistically significant difference between the placebo and lanifibranor treated groups for the primary outcome  Favorable safety profile of lanifibranor observed  Decision to discontinue further developments in the treatment of ...

2019 Drug Insight: Tygacil – Product Details, Sales Assessment, Patent Details, Market Competition, Emerging Therapies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Tygacil – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Tygacil Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the … Continue reading →

2019 Drug Insight: Xopenex – Product Details, Sales Assessment, Patent Details, Market Competition, Emerging Therapies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Xopenex – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Xopenex Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the … Continue reading →

Enbrel – Drug Insight, 2019-2021 with Historical & Forecasted Sales Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Enbrel – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Enbrel Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the … Continue reading →

2019 Drug Insight: Diprivan EML – Product Details, Sales Assessment, Patent Details, Market Competition, Emerging Therapies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Diprivan EML- Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Diprivan EML Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers … Continue reading →

Fusilev – Drug Insight, 2019-2021 with Historical & Forecasted Sales Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fusilev – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Fusilev – Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers … Continue reading →

NextFlex, Profusa Unveils Injectable Biosensor for Continuous Oxygen Monitoring in Tissue

Today at FLEX 2019, integrated biosensor makers Profusa and NextFlex unveiled a skin-worn reader prototype with an injected hydrogel biosensor for continuous oxygen monitoring in tissue. The Lumee™ Oxygen Platform is intended for use in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from continuous monitoring. Lumee Oxygen Hydrogel Biosensor  The...

Naltrexone not associated with serious adverse events, review finds

The opioid antagonist naltrexone does not appear to increase the risk of serious adverse events over placebo, researchers from the University of Manchester have found.

NextFlex and Profusa Unveil Skin-worn Reader Prototype for Continuous Oxygen Monitoring at FLEX 2019

Reader that works with hydrogel sensor injected under the skin developed in only four months at NextFlex facility in San Jose A reader worn on the skin and working in conjunction with an injected hydrogel sensor for real-time oxygen monitoring in tissue is being unveiled today at the FLEX 2019 conference by integrated biosensor maker Profusa and NextFl...

Astellas' Xtandi "significantly improves" progression-free survival in advanced hormone-sensitive prostate cancer

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when combined with androgen deprivation therapy (ADT), in the treatment of male patients with metastatic hormone-sensitive prostate cancer (mHSPC). It was found that the combination met its primary endpoint in Phase 3 trials, significantly reducing the risk of radi...

Further Data Analysis of Bionomics’ Phase 2 Post Traumatic Stress Disorder Trial Shows the Potential for Significant Patient Benefit When Drug Exposure Is Adequate

Additional work undertaken on a drug exposure-response analysis shows a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by CAPS-5 at 12 weeks. Bionomics will now seek FDA guidance on next steps for BNC210 for PTSD including the design of a further trial and whether BNC210 is eligible f...

New Early Breast Cancer Drug To Be Made Available In Singapore Via Special Access Program

- Specialised Therapeutics Asia to make NERLYNX® (neratinib) available to women in Singapore - Five-year follow up data shows NERLYNX reduces risk of invasive disease recurrence or death by 42% in women with early-stage, HER2+/HR+ breast cancer[1] - Subsidised Singapore Special Access Program open today to patients with HER2-overexpressing cancers ...

Friday 15th February 2019

Company Profile for Novus Therapeutics, Inc.

Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device co...

NSAIDs Overtake Opioids As The Top Workers’ Comp Drug Group; Dermatologicals Are Most Costly

A new California Workers’ Compensation Institute (CWCI) study finds that non-steroidal anti-inflammatories (NSAIDs) have supplanted opioids as the most common therapeutic drug group prescribed to injured workers in California, while payment data show that both dermatological medications and anticonvulsants now rank ahead of opioids in terms of total reim...

Temodar: Drug Insight, 2019-2021 with Historical & Forecasted Sales Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Temodar: Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Temodar: Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global … Continue reading →

Ambisome: Drug Insight, 2019-2021 with Historical & Forecasted Sales Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ambisome: Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Ambisome: Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global … Continue reading →

Testogel: Drug Insight, 2019-2021 with Historical & Forecasted Sales Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Testogel: Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Testogel: Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global … Continue reading →

Zenhale: Drug Insight, 2019-2021 with Historical & Forecasted Sales Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Zenhale – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Zenhale Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the … Continue reading →

Lumigan RC – Drug Insight, 2019-2021 with Historical & Forecasted Sales Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Lumigan RC – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Lumigan RC Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report … Continue reading →


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks